Magnetic Resonance Guided Therapy of Cardiac Arhythmia ( MaRGiTA)

该项目将开发用于心律失常微创治疗的新型设备和成像技术，心律失常是影响英国5.3%人口的主要医疗保健问题。目前心律失常的诊断和治疗是在x线指导下进行的。这种成像方式不提供3D信息，也没有软组织对比，整个过程需要几个小时，导致患者和医务人员暴露在严重的辐射下。该项目将开发首个磁共振（MR）引导心律失常治疗程序，使用一种新型导管装置。新方法将完全避免辐射剂量。此外，非侵入性核磁共振技术也将发展成为心律失常治疗的生物标志物。该项目将分三个阶段进行。阶段1。原型：在第一阶段，将开发导管原型和核磁共振跟踪技术。与此同时，将开发成像和量化消融病变的MR技术，并在x射线下使用标准消融导管进行病变测试，随后在我们的X-MR设备中进行MR评估。阶段2。临床前试验：在第二阶段，导管原型和MR消融病变成像将在临床前模型中进行优化和测试。阶段3。临床可行性。在第三阶段，将开发临床导管原型，并在获得监管部门批准后，将在有限数量的患者中进行测试。

This project will develop novel devices and imaging technology for minimal-invasive treatment of cardiac arrhythmias, a major healthcare problem affecting 5.3% of the UK population. Currently diagnosis and treatment of cardiac arrhythmia is performed under X-ray guidance. This imaging modality offers no 3D information and no soft tissue contrast, the procedure takes several hours, resulting in significant radiation exposure to patient and medical staff. This project will develop the first Magnetic Resonance (MR) guided arrhythmia therapy procedure using a novel catheter device. The new procedure will avoid radiation dose completely. Furthermore, non-invasive MR-techniques will also be developed as a biomarker of the arrhythmia treatment. The project will be performed in three phases.Phase 1. Prototyping: In the first phase catheter prototypes and MR-tracking techniques will be developed. In parallel, MR-techniques to image and quantify ablation lesions will be developed and tested with lesions made by standard ablation catheters under X-ray and subsequent evaluation under MR in our X-MR facilities. Phase 2. Preclinical Test: During the second phase catheter prototypes and MR ablation lesion imaging will be optimized and tested in a preclinical model.Phase 3. Clinical Feasibility. During the third phase clinical catheter prototypes will be developed and after obtaining regulatory approval, these will be tested in a limited number of patients.